Lymphoid Leukemia

Subscribe to Selected New Research on Lymphoid Leukemia

1273 relevant articles (69 outcomes, 81 trials/studies) found for this Disease

Description: Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.

Also Known As:

Leukemia, Lymphoid; Leukemias, Lymphocytic; Leukemias, Lymphoid; Lymphocytic Leukemias; Lymphoid Leukemias; Leukemia, Lymphocytic; Lymphocytic Leukemia

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
2.	Leukemia
3.	Lymphoma (Lymphomas)
4.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
5.	Neoplasms (Cancer)

Experts

1.	Imai, K: 5 articles (05/2001 - 07/2000)
2.	Katsuzaki, H: 5 articles (05/2001 - 07/2000)
3.	Hibasami, H: 5 articles (05/2001 - 07/2000)
4.	Komiya, T: 5 articles (05/2001 - 07/2000)
5.	Hajos, Silvia E: 3 articles (08/2004 - 01/2002)
6.	Alvarez, Elida: 3 articles (08/2004 - 01/2002)
7.	Miyahara, Y: 3 articles (05/2001 - 07/2000)
8.	Tura, Sante: 2 articles (12/2006 - 09/2002)
9.	Garcia, Mariana: 2 articles (08/2004 - 05/2003)
10.	Lopes, Eloisi C: 2 articles (05/2003 - 01/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Lymphoid Leukemia:

1.	Cytarabine (Cytosar-U)FDA LinkGeneric 01/01/1986 - "Low-dose Ara-C can cause complete remission of acute non-lymphocytic leukemia: differentiation induction?" 11/01/1979 - "The activity of conjugates I and II against L1210 lymphoid leukemia in female mice (C3D2F1/J) was significantly greater than that of ara-C alone or in combination with the steroid. " 01/01/1983 - "While the majority of patients under 70 years of age with acute non-lymphocytic leukemia enter remission when treated with a combination of cytosine arabinoside and an anthracycline antibiotic, 20-45% of patients do not. " 04/01/1994 - "The in vitro growth inhibitory activities of the ara-C derivatives (4) against murine lymphocytic leukemia L1210 cells indicate that prodrug to drug conversion readily occurs. " 01/20/1990 - "A case of two repeated CNS recurrences of acute non-lymphocytic leukemia (M2) was treated with intermediate dose Ara-C therapy and achieved 2 complete remissions. " Order ALL the reference details at left...
2.	Daunorubicin (Cerubidine)FDA LinkGeneric 04/01/1998 - "The aim of this study was to evaluate the frequency and the role of a PGP and an LRP overexpression in affecting the intracellular daunorubicin accumulation (IDA) and in predicting the therapy outcome on a subset of overt secondary acute non lymphocytic leukemias (ANLL). " 01/01/1979 - "Ten of 19 adult patients (53%) with acute non-lymphocytic leukemia achieved a complete remission (CR) after receiving combination therapy with daunorubicin and cytosine arabinoside. " 02/01/1986 - "A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia." 05/01/1995 - "An effective salvage regimen with aclarubicin for daunorubicin-resistant acute non-lymphocytic leukemia in children." 01/01/1990 - "Intracellular pH (pHi) of mouse lymphoid leukemia P388 cells was measured at the wavelength of 518 and 570 nm of fluorescein: pHi of rubomycin-sensitive P388 cells was higher than pHi of the cells resistant to this antitumour antibiotic (6.98 +/- 0.04 and 6.63 +/- 0.03, respectively, P less than 0.001). " Order ALL the reference details at left...
3.	Doxorubicin (Adriamycin)FDA LinkGeneric 12/31/2008 - "In the present study, we demonstrate that JNK stimulates PKCdelta gene expression via c-Jun and ATF2 in response to the anticancer agent doxorubicin (DXR) in mouse lymphocytic leukemia L1210 cells. " 09/01/2006 - "They were evaluated in P388 murine lymphocytic leukemia cell line (P388) in vitro using SRB assay for cytotoxicity and in adriamycin-resistant P388 murine lymphocytic leukemia cell line (P388/ADR) using MTT assay for resistant reversal activity. " 11/01/1992 - "Taking into account the possible regulatory influences of the beta-adrenergic system on lymphocyte proliferation as well as the proposed role of cyclic 3'-5'-adenosine monophosphate (cAMP) in the modulation of multidrug resistance (MDR) in tumour cells, we have tried to assess the status of the interactions between the beta-adrenergic system and a mouse lymphocytic leukemia, the P388, both as a doxorubicin-sensitive (P388) and -resistant (MDR) variant (P388/DXR). " 06/01/1989 - "One representative complex has been screened in vitro and in vivo against P388 lymphocytic leukemia cells sensitive and resistant to adriamycin (P388/S and P388/R). " 11/01/1986 - "Doxorubicin cytotoxicity to P388 lymphocytic leukemia as determined by alkaline elution and established assays." Order ALL the reference details at left...
4.	Etoposide (VP 16)FDA LinkGeneric 12/18/1996 - "A polymerase chain reaction-based technique was used to measure exon 2 + 3 deletions in human lymphoid leukemia CCRF-CEM cells 6 days after either 4-hour or 24-hour treatment with etoposide at clinically relevant concentrations. " 07/01/1991 - "[Long-term oral administration of etoposide (VP-16) for the patients with refractory or relapsed acute non-lymphocytic leukemia]" 07/01/1991 - "We investigated the efficacy of oral etoposide (VP-16) for the patients with acute non-lymphocytic leukemia (ANLL) in relapse or refractory to the standard chemotherapy. " 07/01/1993 - "Eight cases with poor prognosis hematological malignancies (non-Hodgkin lymphoma, 6 cases; acute non-lymphocytic leukemia, 2 cases) and nine cases with non-hematological malignancies were treated with high dose etoposide (VP16) containing regimen followed by autologous hemopoietic stem cell transplantation. " 01/01/1985 - "Fourteen patients with refractory acute non-lymphocytic leukemia were entered into a dose-seeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days. " Order ALL the reference details at left...
5.	fludarabineIBA 01/01/2004 - "Therefore, with equivalent efficacy and tolerability to the intravenous preparation, oral fludarabine gives the hematologist an important new option in the management of chronic lymphocytic leukemia." 11/01/2002 - "He had had chronic lymphoid leukemia for 11 years and had been treated 5 months earlier with 3 courses of fludarabine. " 11/01/2002 - "[Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia]" 01/01/2000 - "AIM: To try effectiveness of fludarabine monotherapy in verified chronic lymphoid leukemia (CLL) in pretreated patients. " 01/01/2000 - "[Fludarabine treatment of chronic lymphoid leukemia]" Order ALL the reference details at left...
6.	DNA (Deoxyribonucleic Acid)IBA 02/01/2004 - "METHODS: The DNA of peripheral blood leucocytes from lymphoid leukemia patients were extracted for amplification of the TCR-gamma gene rearrangement with the consensus primers and touch-down PCR. " 12/01/2001 - "These complexes inhibit the growth of P388 lymphocytic leukemia cells and their targets are DNA. " 02/01/2001 - "These agents suppressed P388 lymphocytic leukemia DNA synthesis after 60 min at 100 microM. " 12/01/2000 - "In L1210 lymphoid leukemia cell the complexes inhibited preferentially DNA synthesis over 60 min at 25 to 100 microM. " 09/01/1998 - "Interestingly, the carboxyflavins were able to prevent DNA synthesis in the murine lymphoid leukemia cell line L1210 in vitro; almost complete inhibitory levels were achieved in the range of less than 10 microM." Order ALL the reference details at left...
7.	Vincristine (Oncovin)FDA LinkGeneric 06/01/1994 - "This results in a dramatic improvement in the therapeutic activity of liposomal vincristine as measured using a murine P388 lymphocytic leukemia model. " 01/01/2002 - "Multidrug resistance (MDR) lines from a murine T-cell lymphoid leukemia were selected in increasing vincristine (VCR) or doxorubicin (DOX) concentrations. " 01/01/2002 - "Dissimilar invasive and metastatic behavior of vincristine and doxorubicin-resistant cell lines derived from a murine T cell lymphoid leukemia." 02/01/1990 - "Liposome encapsulation of vincristine also enhanced the antitumor activity against murine P388 and L1210 lymphocytic leukemia models. " 01/01/1984 - "There was no change in the activity pattern of 5-fluorouracil against L1210 or vincristine against P388 lymphocytic leukemia respectively, which are sensitive to these drugs. " Order ALL the reference details at left...
8.	Mitoxantrone (Novantrone)FDA LinkGeneric 12/01/1998 - "In a phase I-II study, the authors evaluated the intracellular pharmacokinetics, toxicity, and efficiency of a high dose of mitoxantrone given as first induction in acute non-lymphocytic leukemia. " 01/01/1985 - "Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy. " 12/01/1998 - "High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study." 01/01/1996 - "Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia." 01/01/1991 - "P388/R, the adriamycin (ADR) resistant subline of murine P388 lymphocytic leukemia was cross-resistant to the drug mitoxantrone (MTN). " Order ALL the reference details at left...
9.	Prednisolone (Predate)FDA LinkGeneric 03/01/1981 - "[Treatment of acute non-lymphocytic leukemia with concurrent administration of N4-behenoyl-beta-D-arabinofuranosylcytosine, aclacinomycin A, 6-mercaptopurine and prednisolone; a pilot study (author's transl)]" 01/20/1990 - "A 55-year-old male with acute non-lymphocytic leukemia (M2) achieved complete remission by combination chemotherapy of Behenoyl-ara-C, Daunorubicin, 6-Mercaptopurine and Prednisolone in July, 1985. " 09/01/1982 - "In this study the duration of complete remission by daunomycin, cytosine arabinoside (Ara-C), 6MP and prednisolone (DCMP) therapy using a large dose of Ara-C (200 mg) (protocol 2M-80) was compared with that of DCMP therapy with a low dose of Ara-C (80-160 mg) in acute non-lymphocytic leukemia (ANLL). " 11/01/1988 - "It was found that this liver injury was irreversible and intimately related to combination chemotherapy with the DCMP regimen (daunorubicin, cytosine arabinoside, 6MP and prednisolone) for acute non-lymphocytic leukemia (ANLL). " 11/01/1989 - "The regimens consisted of mitoxantrone plus cytosine arabinoside for 17 patients with acute non-lymphocytic leukemia (ANLL) and mitoxantrone accompanied with vincristine and prednisolone for 11 patients with acute lymphoblastic leukemia (ALL). " Order ALL the reference details at left...
10.	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 06/01/1992 - "The supra-additive terminal differentiation exhibited by the mixture of G-CSF and RA suggests that these agents should be evaluated for the therapeutic efficacy of the combination in patients with acute non-lymphocytic leukemia." 11/01/1989 - "Combination of G-CSF with anti-leukemic agents for the treatment of refractory and relapsed acute non-lymphocytic leukemia (ANLL) or as the conditioning for bone marrow transplantation to refractory ANLL patients was found to be quite effective. " 12/01/1995 - "The mean Mg concentration of granulocytes obtained from lymphocytic leukemia, myelocytic leukemia, infection, and G-CSF patients and from the control group was 3.2 (+/-0.9), 3.4 (+/-0.5), 3.8 (+/-0.6), 4.5 (+/-0.6), and 4.6 (+/-0.6) fmol/cell, respectively. " 12/01/1995 - "The mean (+/-SD) Mg content of MBCs isolated from patients diagnosed with lymphocytic leukemia, myelocytic leukemia, or infection; from patients treated with granulocyte colony-stimulating factor (G-CSF); and from healthy volunteers (control group) was 2.3 (+/-0.6), 3.3 (+/-0.5), 4.1 (+/-0.8), 3.9 (+/-0.4), and 3.9 (+/-0.6) fmol/cell, respectively. " 07/01/1996 - "Donors were mobilized with granulocyte colony-stimulating factor 5 to 10 microgram/kg/d for 6 days and underwent two to three leukapheresis on days +5, +6, +7. The median cell yield per donor expressed/kg of recipients body weight was as follows: nucleated cells 13 x 10(8)/kg; CD34+ cells 6 x 10(6)/kg; colony-forming unit-granulocyte macrophage 38 x 10(4)/kg, and CD3+ cells 449 x 10(6)/kg. The diagnoses were chronic myeloid leukemia (n = 4), acute myeloid (n = 9) or lymphoid leukemia (n = 2), acute myelofibrosis (n = 2), multiple myeloma (n = 1), lymphoma (n = 6), chronic lymphocytic leukemia (n = 1) myelodysplasia (n = 6). " Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/1986 - "HMC lymphoid leukemia appears to differ from typical adult ALL in that it has a female predominance, a relatively indolent early clinical course that lasts 1 year or longer, and it manifests the possibility of survival for 1 or 2 years despite the failure to achieve a complete remission with chemotherapy. " 02/01/1979 - "Overshoot phenomenon of phytohemagglutinin response after chemotherapy and its relationship to remission in acute non-lymphocytic leukemia." 03/15/1980 - "Induced acute non-lymphocytic leukemia following long-term chemotherapy: a study of 20 cases." 05/01/2009 - "Risk factors which can predict for poor response to chemotherapy can now be identified in acute myeloid as well as lymphoid leukemia, based on phenotype, cytogenetics, molecular genetics and response to therapy. " 03/01/2008 - "Chemotherapy for myeloid and lymphoid leukemia simultaneously produced good response in the patients. " Order ALL the reference details at left...
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 04/01/1991 - "One hundred and seven consecutive patients with acute non-lymphocytic leukemia (ANL) aged less than 56 years were allocated to receive either allogeneic (allo-BMT) or autologous bone marrow transplantation (auto-BMT) when first complete remission (CR1) was achieved. " 08/01/1991 - "These results suggest that autologous bone marrow transplantation purged with 4HC is an effective and useful treatment for children with acute non-lymphocytic and lymphocytic leukemia who have no HLA-identical donor." 12/01/2006 - "Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation." 04/01/1991 - "Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission." 07/01/2003 - "Current treatment results of allogeneic bone marrow transplantation for acute myeloid and lymphoid leukemia." Order ALL the reference details at left...
3.	Transplantation (Transplant Recipients) 07/01/1989 - "Engraftment and transfusion requirements after allogeneic marrow transplantation for patients with acute non-lymphocytic leukemia in first complete remission." 02/01/1990 - "Of 13 patients with acute non-lymphocytic leukemia and variants (11 who were transplanted in relapse) three died without relapse, three have relapsed and seven survive disease free from 9 to 27 months (median 20 months) after transplantation.(ABSTRACT TRUNCATED AT 250 WORDS)" 01/01/2009 - "[Characteristics of the morphofunctional condition of cell populations by the modal cell class in response to transplantation of lymphocytic leukemia p-388]" 01/01/1992 - "The survival effect for the conjugate was assessed in vivo against p388 lymphocytic leukemia in female CDF1 mice by intraperitoneal (i.p.) transplantation/i.p. " 08/01/1982 - "Long-term disease-free survivors of acute non-lymphocytic leukemia treated either by chemotherapy or by chemoradiotherapy and marrow transplantation." Order ALL the reference details at left...
4.	Combination Drug Therapy (Combination Chemotherapy) 07/01/1983 - "Twenty-two patients with adult acute non-lymphocytic leukemia treated with intensive combination chemotherapy between November 1975 and April 1982 were retrospectively analyzed to see if we could find useful clinical parameters which could predict those patients who, after failing their initial treatment cycle, would respond to subsequent cycles of the same regimen. " 08/15/1980 - "Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia." 03/01/1971 - "Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia." 12/01/2006 - "This review will summarize recent advances in the biology and the management of chronic lymphocytic leukemia, including prognostic factors, pointing mainly on combination chemotherapy based on nucleoside analogs and monoclonal antibodies. " 11/01/1982 - "[DCTP (I) combination chemotherapy of adult acute non-lymphocytic leukemia]" Order ALL the reference details at left...
5.	Transplants (Transplant) 02/04/2003 - "The underlying diseases of the patients were lymphocytic leukemia and genetic deficiency of the immune system, and they survived between 1 and 9 months after transplant. " 04/01/1997 - "Haploidentical related umbilical cord blood stem cell transplant in a child with acute non-lymphocytic leukemia." 02/01/2000 - "Allogeneic CD34-selected peripheral stem cell transplant for acute non-lymphocytic leukemia (FAB M5a) developed from juvenile chronic myelogenous leukemia." 04/01/1993 - "RESULTS: Four patients were diagnosed of pulmonary toxoplasmosis, three being immunosuppressed (one renal transplant, one with chronic lymphoid leukemia and one intravenous drug user HIV seronegative) and the remaining one healthy. " 02/01/1978 - "The lymphocytic leukemias that developed in the 2 LSH/SsLak inbred hamsters were established as tumor transplants in vivo and as permanent cell lines in vitro." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Lymphoid Leukemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 69 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>